EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel 1,2,3-Triazole-Containing Quinoline–Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking

Luka Krstulović, Katarina Mišković Špoljarić, Vesna Rastija iD, Nikolina Filipović iD, Miroslav Bajić, Ljubica Glavaš-Obrovac iD

Molecules · 06.10.2023 · 28 (19) · 6950

DOI: 10.3390/molecules28196950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 06.10.2023. Verfasst von Luka Krstulović und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Quinolines, Lymphoma. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Veterinary Medicine, University of Zagreb, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, the Faculty of Veterinary Medicine, University of Zagreb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The newly synthesized quinoline–benzimidazole hybrids containing two types of triazole-methyl-phenoxy linkers were characterized via NMR and elemental analysis. Additional derivatization was achieved by introducing bromine at the C-2 position of the phenoxy core. These novel hybrids were tested for their effects on the growth of the non-tumor cell line MRC-5 (human fetal lung fibroblasts), leukemia and lymphoma cell lines: Hut78, THP-1 and HL-60, and carcinoma cell lines: HeLa and CaCo-2. The results obtained, presented as the concentration that achieves 50% inhibition of cell growth (IC50 value), show that the compounds tested affect tumor cell growth differently depending on the cell line and the dose applied (IC50 ranged from 0.2 to >100 µM). The quinoline–benzimidazole hybrids tested, including 7-chloro-4-(4-{[4-(5-methoxy-1H-1,3-benzo[d]imidazol-2-yl)phenoxy]methyl}-1H-1,2,3-triazol-1-yl)quinoline 9c, 2-(3-bromo-4-{[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 10e, 2-{4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 14e and 2-{3-bromo-4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 15e, arrested the cell cycle of lymphoma (HuT78) cells. The calculated ADMET properties showed that the synthesized compounds violated at most two of Lipinski’s rules, making them potential drug candidates, but mainly for parenteral use due to low gastrointestinal absorption. The quinoline–benzimidazole hybrid 14e, which was shown to be a potent and selective inhibitor of lymphoma cell line growth, obtained the highest binding energy (−140.44 kcal/mol), by docking to the TAO2 kinase domain (PDB: 2GCD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesLymphomaHumansTriazolesStructure-Activity RelationshipCaco-2 CellsBenzimidazolesMolecular Docking Simulation

Stichwörter der Autor:innen

1,2,3-triazole-containing quinoline–benzimidazole hybridsantiproliferative effectdockingin silico ADMEsynthesis

Substanzen

TriazolesQuinolinesBenzimidazoles

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia.
  • Department of Medicinal Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Josipa Huttlera 4, 31000 Osijek, Croatia.
  • Faculty of Agrobiotechnical Sciences Osijek, Josip Juraj Strossmayer University of Osijek, Vladimira Preloga 1, 31000 Osijek, Croatia.
  • Department of Chemistry, Josip Juraj Strossmayer University of Osijek, Cara Hadrijana 8a, 31000 Osijek, Croatia.

ORCID-Profile: Vesna Rastija, Nikolina Filipović, Ljubica Glavaš-Obrovac

Förderung

  • Faculty of Veterinary Medicine, University of Zagreb
  • Faculty of Medicine, Josip Juraj Strossmayer University of Osijek
  • the Faculty of Veterinary Medicine, University of Zagreb
  • the Faculty of Medicine, Josip Juraj Strossmayer University of Osijek

Zitieren

APA

Krstulović, L., Mišković Špoljarić, K., Rastija, V., Filipović, N., Bajić, M., & Glavaš-Obrovac, L. (2023). Novel 1,2,3-Triazole-Containing Quinoline–Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking. Molecules, 28(19), 6950. https://doi.org/10.3390/molecules28196950

Vancouver

Krstulović L, Mišković Špoljarić K, Rastija V, Filipović N, Bajić M, Glavaš-Obrovac L. Novel 1,2,3-Triazole-Containing Quinoline–Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking. Molecules. 2023;28(19):6950. doi:10.3390/molecules28196950

BibTeX
@article{Krstulovi2023,
  author = {Krstulović, Luka and Mišković Špoljarić, Katarina and Rastija, Vesna and Filipović, Nikolina and Bajić, Miroslav and Glavaš-Obrovac, Ljubica},
  title = {Novel 1,2,3-Triazole-Containing Quinoline–Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {19},
  pages = {6950},
  doi = {10.3390/molecules28196950}
}
Kostenlos starten →